NCT04230109View on ClinicalTrials.gov

Sacituzumab Govitecan In TNBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2029

Conditions
Invasive Breast CancerTriple Negative Breast CancerER-Negative Breast CancerPR-Negative Breast CancerHER2-negative Breast Cancer
Interventions
DRUG

Sacituzumab Govitecan

Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)

DRUG

Pembrolizumab

Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)

Trial Locations (5)

02115

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

RECRUITING

Massachusetts General Hospital, Boston

01923

RECRUITING

Massachusetts General Hospital - North Shore Cancer Center, Danvers

02462

RECRUITING

Massachusetts General Hospital at Newton-Wellesley Hospital, Newton

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Massachusetts General Hospital

OTHER